Your search history is turned on.
Date: April 22, 2024 Jurisdictions: Alberta, British Columbia
Microsoft Word - 2024 04 22 - UI announces new PP and results of AGM on April 18 -FINAL Universal Ibogaine Announces Private Placement Financing and the Results of the Annual Meeting of Shareholders Calgary, AB April 22, 2024 Universal Ibogaine Inc. (TSXV:IBO) (UI or the Company), a life sciences company with a mission to research and deliver m...
Date: April 17, 2024 Jurisdictions: Alberta, British Columbia, Manitoba
Create report of exempt distribution (Form 45-106F1) Form 45-106F1 Report of Exempt Distribution ITEM 1 - REPORT TYPE New report Amended report If amended, provide filing date of report that is being amended. (YYYY-MM-DD) ITEM 2 - PARTY CERTIFYING THE REPORT Indicate the party certifying the report (select only one). For guidance regarding whether an ...
Date: April 12, 2024 Jurisdictions: Alberta, British Columbia
Microsoft Word - 2024 04 12 - UI announces new private placement financing at $0.02 - DRAFT3 Universal Ibogaine Announces New Private Placement Financing Calgary, AB April 12, 2024 Universal Ibogaine Inc. (TSXV:IBO) (UI or the Company), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, advises t...
Date: April 10, 2024 Jurisdictions: Alberta, British Columbia
Universal Ibogaine announces closing of private placement financing Calgary, AB April 10, 2024 Universal Ibogaine Inc. (TSXV:IBO) (UI or the Company), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, is pleased to announce that it has closed its previously announced (see News Release of Febru...
Date: April 8, 2024 Jurisdictions: Alberta, British Columbia
Microsoft Word - 2024 04 08 UI advises of management change FINAL Universal Ibogaine Advises of Management Change Calgary, AB April 8, 2024 Universal Ibogaine Inc. (TSXV:IBO) (UI or the Company), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, advises that Ian Rabb, Chief Clinics Officer, is ...
Date: March 28, 2024 Jurisdictions: Alberta, British Columbia
MD&A for the Q2 period ended January 31, 2024 1 UNIVERSAL IBOGAINE INC. Managements Discussion and Analysis (MD&A) As at and for the Q1 3-month period ended January 31, 2023 The following MD&A presented for Universal Ibogaine Inc. (UI or the Company) was prepared by management based on information available as at March 27, 2024...
Microsoft Word - 52-109 FV2 Cert by UI CFO for Q2 ended Jan 31 2024 Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, Gregory Leavens, Chief Financial Officer, certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Universal Ibogaine In...
Microsoft Word - 52-109 FV2 Cert by UI CEO for Q2 ended Jan 31 2024 Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, Nicholas Karos, Chief Executive Officer, certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Universal Ibogaine Inc...
Greenstone - Financial Statements - Prelim (01549002.DOCX;2) page | 1 UNIVERSAL IBOGAINE INC. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE 6-MONTH PERIODS ENDED JANUARY 31, 2024 AND 2023 page | 2 NOTICE OF NO AUDITOR REVIEW OF ...
Date: March 19, 2024 Jurisdictions: Alberta, British Columbia
Notice of Availability of Proxy Materials for Universal Ibogaine Inc. Annual Meeting Meeting Date and Time: April 18, 2024, at 3:00 p.m. (Mountain time) Location: The offices of CAS Corporate Governance Services Inc., Suite 600, 815 8th Avenue SW, Calgary, Alberta Please be advised that the proxy materials for the above noted securit...